y demonstrate the potential pazopanib offers as a future therapeutic option not only in renal cell cancer, but across many different tumor types," said Debasish Roychowdhury, MD, Vice President, Global Clinical Development, Oncology Medicine Development Centre, GSK. "The broad clinical development program for pazopanib, in various cancers as monotherapy and in combination therapy, including combinations with Tykerb, underscores our continued commitment to delivering effective new treatments for patients with cancer."
Ovarian cancer study. This ongoing Phase II open-label, monotherapy study is evaluating pazopanib in patients with cancer of the ovary, fallopian tube or peritoneum, who have failed standard platinum-based therapy. Treatment is continued until disease progression, withdrawal due to AEs, or withdrawal of consent. Biological activity (measured as a decrease in CA-125, a biologic marker of clinical activity) was seen in nine (41%) of 22 evaluable patients with relapsed disease. The most common AEs were diarrhea, nausea, abdominal pain, fatigue, and vomiting. Please see safety considerations below.
Globally, ovarian cancer (204,000 cases and 125,000 deaths) is the sixth most common cancer and the seventh most common cause of death from cancer in women. The majority of patients with ovarian cancer will have advanced disease at the time of initial diagnosis. Typically, these patients are managed with surgery followed by combination chemotherapy. Although the majority of patients will respond initially to firstline therapy, recurrent disease remains a considerable problem.
Soft tissue sarcoma study. STS is a disease in which malignant cancer cells begin growing in soft tissues, such as muscles, tendons, connective tissues, fat, blood vessels, nerves, and tissues around joints. This ongoing Phase II study is evaluating the effect of pazopanib in patients with advanced STS who have failed prior therapy for advanced diseaPage: 1 2 3 4 Related medicine news :1
. Experimental treatment for Ebola Virus Shows promising results in mice2
. New Prostate Cancer Vaccine Shows Promise3
. Ebola Treatment Shows Promise4
. New Drug Shows Significant Improvement In HIV-related Heart Condition5
. Greek Study Shows Living In The Hills May Be Healthier
. Research Shows Carbon Monoxide Prevents Inflammations7
. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly8
. Novartis MS Drug Shows Promising Results9
. MRI Shows Emotional Changes During Menstrual Cycle 10
. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia 11
. AIDS drug GS 9137 Shows Promise